Virginia Bottomley - Smith Nephew Non-Executive Independent Director
SNNUF Stock | USD 12.31 0.40 3.15% |
Director
Rt. Hon. Baroness Virginia Hilda Brunette Maxwell Bottomley is NonExecutive Independent Director of Smith Nephew PLC., since April 12, 2012. She is a Member of the Remuneration Committee and Nomination Governance Committee in April 2014 and will join the Compliance Culture Committee in April 2019. Career and experience Virginia gained her MSc in Social Administration from the London School of Economics following her first degree. She was appointed a Life Peer in 2005 following her career as a Member of Parliament between 1984 and 2005. She served successively as Secretary of State for Health and then Culture, Media and Sport. Virginia was formerly a Director of Bupa and AkzoNobel NV. She is currently a Director of International Resources Group Limited, where she is Chair of Board CEO Practice at Odgers Berndtson. She is a member of the International Advisory Council of Chugai Pharmaceutical Co., Chancellor of University of Hull and Sheriff of Kingston upon Hull. She is a Trustee of The Economist Newspaper. Skills and competencies Virginias extensive experience within Government, particularly as Secretary of State for Health, brings a unique insight into the healthcare system both in the UK and globally, whilst her experience on the board of Bupa brings an understanding of the private healthcare sector and an insight into the needs of our customers. Her experience running the board practice at a search firm gives her a valuable skillset as a member of the Nomination Governance Committee and Remuneration Committee. Her long association with Hull, the home of many of our UK employees, also brings an added perspective. since 2012.
Age | 70 |
Tenure | 12 years |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
David Wichmann | Boston Scientific Corp | 58 | |
Charles Dockendorff | Boston Scientific Corp | 66 | |
Steven Altman | DexCom Inc | 56 | |
Cecil Pickett | Zimmer Biomet Holdings | 70 | |
William Link | Edwards Lifesciences Corp | 73 | |
N Nicholas | Boston Scientific Corp | 74 | |
Nelda Connors | Boston Scientific Corp | 55 | |
Donna James | Boston Scientific Corp | 63 | |
John Cardis | Edwards Lifesciences Corp | 73 | |
Srikant Datar | Stryker | 68 | |
Michael Leavitt | Medtronic PLC | 69 | |
Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
Eric Topol | DexCom Inc | 63 | |
Robert Alpern | Abbott Laboratories | 70 | |
John Stratton | Abbott Laboratories | 60 | |
Roch Doliveux | Stryker | 64 | |
Syed Jafry | Zimmer Biomet Holdings | 57 | |
Samuel Scott | Abbott Laboratories | 75 | |
Anne Myong | Align Technology | 51 | |
Shirley Jackson | Medtronic PLC | 70 | |
Sally Blount | Abbott Laboratories | 59 |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew Plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director | ||
Michael Friedman, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Director | ||
Deepak Nath, CEO Director | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Director | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Rodrigo Bianchi, President IRAMEA | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Non-Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Director | ||
Simon Fraser, President - Advanced Wound Management | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, CFO, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, VP Communications | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Glenn Warner, President - Advanced Wound Management | ||
Robin Freestone, Non-Executive Director | ||
Paul Connolly, Pres Operations | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Director | ||
Mark Gladwell, President - Global Operations | ||
Andrew Swift, VP Relations | ||
Vasant Padmanabhan, President - Research & Development | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Joseph Papa, Non-Executive Independent Director | ||
Ingeborg Oie, VP, Investor Relations | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President Europe and Canada | ||
Ian Barlow, Non-Executive Independent Director | ||
Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |